Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August...
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August...
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”)...
WESTFORD, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone...
ROSCREA, Ireland and FREIBURG, Germany, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed...
The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --...
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing...
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™...
Dr. Alan Durkin, a dual board-certified plastic and reconstructive surgeon and the founder of Ocean Drive Plastic Surgery in Vero...
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone...
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of...
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase...
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10...
Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc...
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that...
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin...
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is...
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the...